Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases

Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2010, Pages 714-720

  Joy, Melanie S ^a,b   Frye, Reginald F ^c   Stubbert, Kristi ^d   Brouwer, Kim R ^b   Falk, Ronald J ^a   Kharasch, Evan D ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANCA vasculitis; Bupropion; CYP2B6; Glomerulonephritis; Hydroxybupropion; Lupus nephritis; Single dose pharmacokinetics

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; RADAFAXINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ACTIVITY; ENANTIOMER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CHRONIC DISEASE; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; STEREOISOMERISM;

EID: 77953788398     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009353031     Document Type: Article

References (39)

1. Coresh J., Selvin E., Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007 ; 298 (17). 2038-2047. (Pubitemid 350074801)
2. System USRD. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases ; 2008.
3. Guevin C., Michaud J., Naud J., Leblond FA, Pichette V. Downregulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002 ; 137 (7). 1039-1046. (Pubitemid 35440744)
4. Naud J., Michaud J., Leblond FA, Lefrancois S., Bonnardeaux A., Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008 ; 36 (1). 124-128.
5. Simard E., Naud J., Michaud J., et al. Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol. 2008 ; 19 (7). 1352-1359.
6. Nolin TD, Naud J., Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008 ; 83 (6). 898-903.
7. Chainuvati S., Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail." Clin Pharmacol Ther. 2003 ; 74 (5). 437-447.
8. Zgheib NK, Frye RF, Tracy TS, Romkes M., Branch RA Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther. 2006 ; 80 (3). 257-263.
9. Nolin TD, Appiah K., Kendrick SA, Le P., McMonagle E., Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006 ; 17 (9). 2363-2367.
10. Dreisbach AW, Japa S., Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003 ; 73 (5). 475-477.
11. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003 ; 73 (5). 427-434.
12. Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993 ; 54 (6). 612-620.
13. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004 ; 19 (7). 1842-1848.
14. Turpeinen M., Koivuviita N., Tolonen A., et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol. 2007 ; 64 (2). 165-173.
15. Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke: a single dose study. Nephron Clin Pract. 2004 ; 97 (3). c83 - c89.
16. Rendic S., Di Carlo FJ Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997 ; 29 (1-2). 413-580.
17. Nolan D., Phillips E., Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis. 2006 ; 42 (3). 408-410.
18. Hesse LM, Venkatakrishnan K., Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000 ; 28 (10). 1176-1183.
19. Roy P., Yu LJ, Crespi CL, Waxman DJ Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 ; 27 (6). 655-666.
20. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003 ; 306 (1). 287-300.
21. Hidestrand M., Oscarson M., Salonen JS, et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinsonĝ€™s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. 2001 ; 29 (11). 1480-1484.
22. Obach RS, Cox LM, Tremaine LM Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 ; 33 (2). 262-270.
23. Walsky RL, Astuccio AV, Obach RS Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 ; 46 (12). 1426-1438.
24. Kharasch ED, Mitchell D., Coles R. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol. 2008 ; 48 (4). 464-474.
25. Coles R., Kharasch ED Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/ MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 857 (1). 67-75.
26. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16 (1). 31-41.
27. Joy MS, Hilliard T., Hu Y., et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009 ; 29 (1). 7-16.
28. Zyban SR [product information]. Middlesex, UK: GlaxoSmithKline; 2006.
29. Turpeinen M., Tolonen A., Uusitalo J., Jalonen J., Pelkonen O., Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005 ; 77 (6). 553-559.
30. Fan L., Wang JC, Jiang F., et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol. 2009 ; 65 (4). 403-409.
31. Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 ; 80 (1). 75-84.
32. Xu H., Loboz KK, Gross AS, McLachlan AJ Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality. 2007 ; 19 (3). 163-170.
33. Coles R., Kharasch ED Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res. 2008 ; 25 (6). 1405-1411.
34. Bondarev ML, Bondareva TS, Young R., Glennon RA Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003 ; 474 (1). 85-93.
35. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004 ; 66 (3). 675-682.
36. Fang QK, Han Z., Grover P., Kessler D., Senanayake CH, Wald SA Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleosphilic substitution on an [alpha]-ketogriflate. Tetrahedron. 2000 ; 11: 3635-3663.
37. Grubb NG, Rudy DW, Brater DC, Hall SD Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a "futile cycle" of elimination. Br J Clin Pharmacol. 1999 ; 48 (4). 494-500.
38. Rudy AC, Knight PM, Brater DC, Hall SD Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. J Pharmacol Exp Ther. 1995 ; 273 (1). 88-93.
39. Chen CY, Chen CS Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol. 1995 ; 40 (1). 67-72.